Study also indicates early treatment may provide best outcomes.
With FDA approval of EpidiolexR, the pace of research on CBD medication is likely to increase.
Tests of NT-3 gene therapy on mouse models suggest potential to treat a host of muscle-wasting conditions.
A new study shows that cannabidiol is effective in children with Lennox-Gastaut syndrome.
Recent applications of adeno-associated virus (AAV) mediated gene therapy have focused mainly on correcting recessively inherited diseases. But what about dominantly inherited disorders? It looks like AAV could be a delivery mechanism for treating those genetic disorders, too.
On May 24, 2019, Zolgensma, a first-of-its-kind gene therapy for spinal muscular atrophy was approved.
